Share Price and Basic Stock Data
Last Updated: February 3, 2026, 2:32 am
| PEG Ratio | 0.14 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lupin Ltd, a prominent player in the pharmaceuticals industry, reported a market capitalization of ₹97,407 Cr and a share price of ₹2,130. The company has demonstrated a consistent upward trajectory in its sales, which rose from ₹4,146 Cr in September 2022 to ₹5,039 Cr by September 2023. This upward trend continued into December 2023, reaching ₹5,197 Cr, and is expected to reach ₹5,768 Cr by December 2024. The total revenue for the trailing twelve months (TTM) stood at ₹24,751 Cr, indicating solid performance in its core operations. Over the past fiscal years, Lupin’s annual sales have also shown growth, climbing from ₹16,405 Cr in FY 2022 to ₹22,708 Cr in FY 2025. This growth reflects the company’s strategic focus on expanding its product portfolio and entering new markets, aligning with the general industry trend of increasing demand for pharmaceuticals.
Profitability and Efficiency Metrics
Lupin Ltd reported a net profit of ₹4,348 Cr for the trailing twelve months, with a significant rise in operating profit margin (OPM) from 11% in September 2022 to 33% by September 2025. The company’s net profit margin also improved markedly, reaching 14.55% in FY 2025, compared to just 2.69% in FY 2023. The return on equity (ROE) and return on capital employed (ROCE) stood at 20.6% and 21.3%, respectively, indicating efficient utilization of equity and capital. Additionally, the interest coverage ratio (ICR) was a robust 18.58x, showcasing the company’s ability to meet its interest obligations comfortably. However, while profitability metrics are impressive, the cash conversion cycle (CCC) reported at 223 days suggests a need for improved efficiency in managing receivables and inventory, which could impact liquidity if not addressed.
Balance Sheet Strength and Financial Ratios
Lupin’s balance sheet reflects a healthy financial position with total borrowings recorded at ₹6,217 Cr against reserves of ₹19,541 Cr. The debt-to-equity ratio stood at 0.29, indicating a manageable level of leverage. The company’s current ratio of 1.87 suggests that it maintains sufficient liquidity to cover short-term obligations. Furthermore, the price-to-book value (P/BV) ratio was reported at 5.38x, which, while above the industry average, indicates market confidence in the company’s growth potential. The retained earnings policy is strong, as evidenced by an earning retention ratio of 88.89%, which supports future growth initiatives. Overall, the financial ratios signal a robust operational framework, although investors should monitor the rising borrowings trend for potential future implications.
Shareholding Pattern and Investor Confidence
The shareholding structure of Lupin Ltd reflects a diverse investor base, with promoters holding 46.89% of the shares, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 20.50% and 26.56%, respectively. The recent decline in promoter shareholding from 47.10% in December 2022 to 46.89% by September 2025 could raise concerns about insider confidence, though it remains substantial. The public shareholding stands at 6.06%, indicating limited retail participation. The total number of shareholders has remained stable at approximately 2,80,256, suggesting sustained interest in the stock. This diversified ownership structure is generally positive, as it can lead to greater market stability and investor interest in the company’s long-term performance.
Outlook, Risks, and Final Insight
Lupin Ltd’s outlook appears positive, supported by its strong revenue growth, profitability metrics, and a solid balance sheet. However, potential risks include the high cash conversion cycle, which may strain liquidity if not improved, and the declining promoter shareholding, which could affect investor sentiment. Additionally, the pharmaceutical sector faces challenges such as regulatory scrutiny and competitive pressures, which could impact future performance. Should Lupin successfully enhance its operational efficiency and maintain its growth trajectory, it could solidify its position in the market. Conversely, any adverse regulatory developments or failure to manage costs effectively could pose significant risks. Overall, while the company is well-positioned for growth, a vigilant approach to the identified risks will be crucial for sustaining its positive momentum in the coming quarters.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 195/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,449 Cr. | 316 | 479/192 | 71.4 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.6 Cr. | 45.3 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 73.2 Cr. | 50.0 | 50.0/17.0 | 174 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,474.81 Cr | 1,084.68 | 46.55 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,146 | 4,322 | 4,430 | 4,814 | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 | 5,667 | 6,268 | 7,048 |
| Expenses | 3,693 | 3,790 | 3,852 | 3,958 | 4,121 | 4,159 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 | 4,706 |
| Operating Profit | 453 | 533 | 578 | 856 | 918 | 1,038 | 997 | 1,241 | 1,340 | 1,356 | 1,321 | 1,727 | 2,341 |
| OPM % | 11% | 12% | 13% | 18% | 18% | 20% | 20% | 22% | 24% | 24% | 23% | 28% | 33% |
| Other Income | 15 | 18 | 37 | 23 | 40 | 29 | 29 | 68 | 42 | 54 | 57 | 79 | 90 |
| Interest | 55 | 84 | 93 | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 | 108 |
| Depreciation | 203 | 220 | 264 | 235 | 248 | 257 | 457 | 248 | 257 | 271 | 393 | 299 | 317 |
| Profit before tax | 210 | 246 | 258 | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 | 2,007 |
| Tax % | 36% | 36% | 6% | 19% | 21% | 16% | 26% | 19% | 19% | 20% | 13% | 14% | 26% |
| Net Profit | 134 | 158 | 242 | 453 | 495 | 619 | 368 | 806 | 859 | 859 | 782 | 1,221 | 1,485 |
| EPS in Rs | 2.85 | 3.37 | 5.19 | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.69 | 18.74 | 16.92 | 26.69 | 32.36 |
Last Updated: January 11, 2026, 2:17 pm
Below is a detailed analysis of the quarterly data for Lupin Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 7,048.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,268.00 Cr. (Jun 2025) to 7,048.00 Cr., marking an increase of 780.00 Cr..
- For Expenses, as of Sep 2025, the value is 4,706.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,541.00 Cr. (Jun 2025) to 4,706.00 Cr., marking an increase of 165.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 2,341.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,727.00 Cr. (Jun 2025) to 2,341.00 Cr., marking an increase of 614.00 Cr..
- For OPM %, as of Sep 2025, the value is 33.00%. The value appears strong and on an upward trend. It has increased from 28.00% (Jun 2025) to 33.00%, marking an increase of 5.00%.
- For Other Income, as of Sep 2025, the value is 90.00 Cr.. The value appears strong and on an upward trend. It has increased from 79.00 Cr. (Jun 2025) to 90.00 Cr., marking an increase of 11.00 Cr..
- For Interest, as of Sep 2025, the value is 108.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 92.00 Cr. (Jun 2025) to 108.00 Cr., marking an increase of 16.00 Cr..
- For Depreciation, as of Sep 2025, the value is 317.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 299.00 Cr. (Jun 2025) to 317.00 Cr., marking an increase of 18.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 2,007.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,416.00 Cr. (Jun 2025) to 2,007.00 Cr., marking an increase of 591.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 14.00% (Jun 2025) to 26.00%, marking an increase of 12.00%.
- For Net Profit, as of Sep 2025, the value is 1,485.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,221.00 Cr. (Jun 2025) to 1,485.00 Cr., marking an increase of 264.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 32.36. The value appears strong and on an upward trend. It has increased from 26.69 (Jun 2025) to 32.36, marking an increase of 5.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:02 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11,286 | 12,770 | 14,256 | 17,367 | 15,797 | 14,665 | 15,375 | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 | 24,751 |
| Expenses | 8,271 | 9,146 | 10,564 | 12,865 | 12,649 | 12,104 | 13,020 | 12,596 | 16,187 | 14,921 | 16,211 | 17,430 | 18,005 |
| Operating Profit | 3,015 | 3,624 | 3,691 | 4,502 | 3,148 | 2,561 | 2,355 | 2,567 | 219 | 1,721 | 3,800 | 5,278 | 6,746 |
| OPM % | 27% | 28% | 26% | 26% | 20% | 17% | 15% | 17% | 1% | 10% | 19% | 23% | 27% |
| Other Income | 105 | 235 | 184 | 106 | -1,310 | 91 | -134 | 138 | 210 | 151 | 131 | 202 | 280 |
| Interest | 27 | 10 | 59 | 153 | 204 | 302 | 363 | 141 | 143 | 274 | 312 | 295 | 355 |
| Depreciation | 261 | 435 | 487 | 912 | 1,086 | 846 | 970 | 887 | 1,659 | 881 | 1,197 | 1,169 | 1,280 |
| Profit before tax | 2,832 | 3,415 | 3,329 | 3,543 | 547 | 1,503 | 887 | 1,676 | -1,372 | 716 | 2,422 | 4,015 | 5,390 |
| Tax % | 34% | 28% | 32% | 28% | 53% | 59% | 130% | 27% | 10% | 38% | 20% | 18% | |
| Net Profit | 1,870 | 2,444 | 2,270 | 2,565 | 258 | 615 | -270 | 1,228 | -1,528 | 448 | 1,936 | 3,306 | 4,348 |
| EPS in Rs | 40.96 | 53.47 | 50.17 | 56.63 | 5.56 | 13.40 | -5.95 | 26.81 | -33.62 | 9.45 | 42.01 | 71.88 | 94.71 |
| Dividend Payout % | 15% | 14% | 15% | 13% | 90% | 37% | -101% | 24% | -12% | 42% | 19% | 17% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 30.70% | -7.12% | 13.00% | -89.94% | 138.37% | -143.90% | 554.81% | -224.43% | 129.32% | 332.14% | 70.76% |
| Change in YoY Net Profit Growth (%) | 0.00% | -37.81% | 20.12% | -102.94% | 228.31% | -282.27% | 698.72% | -779.24% | 353.75% | 202.82% | -261.38% |
Lupin Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 11% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 55% |
| 3 Years: | 60% |
| TTM: | 63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 15% |
| 3 Years: | 44% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 8% |
| 3 Years: | 13% |
| Last Year: | 21% |
Last Updated: September 5, 2025, 9:55 am
Balance Sheet
Last Updated: December 4, 2025, 1:35 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
| Reserves | 6,842 | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 | 17,112 | 19,541 |
| Borrowings | 654 | 537 | 7,178 | 7,966 | 7,143 | 8,496 | 6,305 | 5,129 | 4,158 | 4,542 | 2,922 | 5,448 | 6,217 |
| Other Liabilities | 2,550 | 3,642 | 3,957 | 4,749 | 5,300 | 5,423 | 5,968 | 4,498 | 5,340 | 5,794 | 6,539 | 6,327 | 7,651 |
| Total Liabilities | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 33,500 |
| Fixed Assets | 3,356 | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 | 9,719 | 10,252 |
| CWIP | 304 | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 | 517 | 593 |
| Investments | 178 | 1,658 | 16 | 2,136 | 262 | 2,295 | 2,374 | 2,455 | 900 | 517 | 1,075 | 1,146 | 3,331 |
| Other Assets | 6,297 | 6,451 | 10,862 | 10,910 | 12,798 | 12,639 | 13,557 | 12,028 | 12,224 | 12,690 | 13,026 | 17,596 | 19,325 |
| Total Assets | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 33,500 |
Below is a detailed analysis of the balance sheet data for Lupin Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 91.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 91.00 Cr..
- For Reserves, as of Sep 2025, the value is 19,541.00 Cr.. The value appears strong and on an upward trend. It has increased from 17,112.00 Cr. (Mar 2025) to 19,541.00 Cr., marking an increase of 2,429.00 Cr..
- For Borrowings, as of Sep 2025, the value is 6,217.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 5,448.00 Cr. (Mar 2025) to 6,217.00 Cr., marking an increase of 769.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 7,651.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,327.00 Cr. (Mar 2025) to 7,651.00 Cr., marking an increase of 1,324.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 33,500.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28,978.00 Cr. (Mar 2025) to 33,500.00 Cr., marking an increase of 4,522.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 10,252.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,719.00 Cr. (Mar 2025) to 10,252.00 Cr., marking an increase of 533.00 Cr..
- For CWIP, as of Sep 2025, the value is 593.00 Cr.. The value appears strong and on an upward trend. It has increased from 517.00 Cr. (Mar 2025) to 593.00 Cr., marking an increase of 76.00 Cr..
- For Investments, as of Sep 2025, the value is 3,331.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,146.00 Cr. (Mar 2025) to 3,331.00 Cr., marking an increase of 2,185.00 Cr..
- For Other Assets, as of Sep 2025, the value is 19,325.00 Cr.. The value appears strong and on an upward trend. It has increased from 17,596.00 Cr. (Mar 2025) to 19,325.00 Cr., marking an increase of 1,729.00 Cr..
- For Total Assets, as of Sep 2025, the value is 33,500.00 Cr.. The value appears strong and on an upward trend. It has increased from 28,978.00 Cr. (Mar 2025) to 33,500.00 Cr., marking an increase of 4,522.00 Cr..
Notably, the Reserves (19,541.00 Cr.) exceed the Borrowings (6,217.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -651.00 | -534.00 | -4.00 | -3.00 | -4.00 | -6.00 | -4.00 | -3.00 | 215.00 | -3.00 | 1.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 76 | 116 | 91 | 120 | 128 | 129 | 108 | 95 | 98 | 86 | 88 |
| Inventory Days | 204 | 220 | 276 | 266 | 253 | 283 | 232 | 279 | 261 | 242 | 272 | 292 |
| Days Payable | 152 | 172 | 168 | 189 | 178 | 184 | 162 | 137 | 129 | 136 | 163 | 158 |
| Cash Conversion Cycle | 131 | 124 | 225 | 167 | 195 | 227 | 199 | 249 | 227 | 204 | 195 | 223 |
| Working Capital Days | 81 | 56 | 102 | 63 | 126 | 115 | 33 | 34 | 45 | 32 | 53 | 58 |
| ROCE % | 41% | 40% | 24% | 19% | 10% | 10% | 9% | 9% | -7% | 6% | 16% | 21% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Balanced Advantage Fund | 5,705,582 | 1.11 | 1203.59 | N/A | N/A | N/A |
| HDFC Large Cap Fund | 4,615,980 | 2.4 | 973.74 | N/A | N/A | N/A |
| Mirae Asset Large & Midcap Fund | 4,285,561 | 2.07 | 904.04 | N/A | N/A | N/A |
| HDFC Flexi Cap Fund | 4,200,000 | 0.92 | 885.99 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 2,883,991 | 7.36 | 608.38 | 3,083,991 | 2026-01-25 01:59:43 | -6.49% |
| Mirae Asset Midcap Fund | 2,835,782 | 3.25 | 598.21 | 2,735,782 | 2025-12-15 08:40:45 | 3.66% |
| ICICI Prudential Value Fund | 2,823,402 | 0.97 | 595.6 | N/A | N/A | N/A |
| SBI ELSS Tax Saver Fund | 2,687,887 | 1.74 | 567.01 | N/A | N/A | N/A |
| Nippon India Growth Mid Cap Fund | 2,552,382 | 1.28 | 538.43 | N/A | N/A | N/A |
| Nippon India Multi Cap Fund | 2,520,027 | 1.06 | 531.6 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 71.95 | 42.05 | 9.46 | -33.65 | 26.84 |
| Diluted EPS (Rs.) | 71.95 | 41.87 | 9.41 | -33.65 | 26.72 |
| Cash EPS (Rs.) | 98.02 | 68.74 | 29.20 | 3.28 | 46.59 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 376.77 | 315.41 | 275.67 | 268.91 | 305.45 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 376.77 | 315.41 | 275.67 | 268.91 | 305.45 |
| Revenue From Operations / Share (Rs.) | 497.33 | 439.12 | 365.75 | 360.96 | 334.21 |
| PBDIT / Share (Rs.) | 120.00 | 86.26 | 41.13 | 9.44 | 59.58 |
| PBIT / Share (Rs.) | 94.39 | 59.99 | 21.78 | -27.06 | 40.02 |
| PBT / Share (Rs.) | 87.93 | 53.15 | 15.75 | -30.20 | 36.92 |
| Net Profit / Share (Rs.) | 72.41 | 42.47 | 9.84 | -33.22 | 27.04 |
| NP After MI And SOA / Share (Rs.) | 71.87 | 42.01 | 9.45 | -33.62 | 26.81 |
| PBDIT Margin (%) | 24.12 | 19.64 | 11.24 | 2.61 | 17.82 |
| PBIT Margin (%) | 18.97 | 13.66 | 5.95 | -7.49 | 11.97 |
| PBT Margin (%) | 17.68 | 12.10 | 4.30 | -8.36 | 11.04 |
| Net Profit Margin (%) | 14.55 | 9.67 | 2.69 | -9.20 | 8.08 |
| NP After MI And SOA Margin (%) | 14.45 | 9.56 | 2.58 | -9.31 | 8.02 |
| Return on Networth / Equity (%) | 19.07 | 13.39 | 3.45 | -12.57 | 8.81 |
| Return on Capital Employeed (%) | 21.29 | 17.64 | 7.23 | -9.07 | 11.96 |
| Return On Assets (%) | 11.23 | 7.97 | 1.87 | -7.00 | 5.15 |
| Long Term Debt / Equity (X) | 0.10 | 0.00 | 0.00 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.29 | 0.18 | 0.34 | 0.31 | 0.22 |
| Asset Turnover Ratio (%) | 0.85 | 0.85 | 0.50 | 0.51 | 0.47 |
| Current Ratio (X) | 1.87 | 1.58 | 1.34 | 1.51 | 1.66 |
| Quick Ratio (X) | 1.26 | 0.99 | 0.85 | 0.94 | 1.17 |
| Inventory Turnover Ratio (X) | 4.35 | 0.87 | 0.82 | 0.77 | 0.88 |
| Dividend Payout Ratio (NP) (%) | 11.11 | 9.50 | 42.28 | -19.31 | 22.34 |
| Dividend Payout Ratio (CP) (%) | 8.19 | 5.85 | 13.87 | 225.82 | 12.92 |
| Earning Retention Ratio (%) | 88.89 | 90.50 | 57.72 | 119.31 | 77.66 |
| Cash Earning Retention Ratio (%) | 91.81 | 94.15 | 86.13 | -125.82 | 87.08 |
| Interest Coverage Ratio (X) | 18.58 | 12.61 | 6.82 | 3.00 | 19.22 |
| Interest Coverage Ratio (Post Tax) (X) | 12.21 | 7.21 | 2.63 | -9.57 | 9.72 |
| Enterprise Value (Cr.) | 94555.16 | 75275.95 | 32506.42 | 36722.71 | 47698.57 |
| EV / Net Operating Revenue (X) | 4.16 | 3.76 | 1.95 | 2.24 | 3.15 |
| EV / EBITDA (X) | 17.26 | 19.15 | 17.37 | 85.62 | 17.65 |
| MarketCap / Net Operating Revenue (X) | 4.07 | 3.68 | 1.77 | 2.07 | 3.05 |
| Retention Ratios (%) | 88.88 | 90.49 | 57.71 | 119.31 | 77.65 |
| Price / BV (X) | 5.38 | 5.16 | 2.36 | 2.79 | 3.36 |
| Price / Net Operating Revenue (X) | 4.07 | 3.68 | 1.77 | 2.07 | 3.05 |
| EarningsYield | 0.03 | 0.02 | 0.01 | -0.04 | 0.02 |
After reviewing the key financial ratios for Lupin Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 71.95. This value is within the healthy range. It has increased from 42.05 (Mar 24) to 71.95, marking an increase of 29.90.
- For Diluted EPS (Rs.), as of Mar 25, the value is 71.95. This value is within the healthy range. It has increased from 41.87 (Mar 24) to 71.95, marking an increase of 30.08.
- For Cash EPS (Rs.), as of Mar 25, the value is 98.02. This value is within the healthy range. It has increased from 68.74 (Mar 24) to 98.02, marking an increase of 29.28.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 376.77. It has increased from 315.41 (Mar 24) to 376.77, marking an increase of 61.36.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 376.77. It has increased from 315.41 (Mar 24) to 376.77, marking an increase of 61.36.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 497.33. It has increased from 439.12 (Mar 24) to 497.33, marking an increase of 58.21.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 120.00. This value is within the healthy range. It has increased from 86.26 (Mar 24) to 120.00, marking an increase of 33.74.
- For PBIT / Share (Rs.), as of Mar 25, the value is 94.39. This value is within the healthy range. It has increased from 59.99 (Mar 24) to 94.39, marking an increase of 34.40.
- For PBT / Share (Rs.), as of Mar 25, the value is 87.93. This value is within the healthy range. It has increased from 53.15 (Mar 24) to 87.93, marking an increase of 34.78.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 72.41. This value is within the healthy range. It has increased from 42.47 (Mar 24) to 72.41, marking an increase of 29.94.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 71.87. This value is within the healthy range. It has increased from 42.01 (Mar 24) to 71.87, marking an increase of 29.86.
- For PBDIT Margin (%), as of Mar 25, the value is 24.12. This value is within the healthy range. It has increased from 19.64 (Mar 24) to 24.12, marking an increase of 4.48.
- For PBIT Margin (%), as of Mar 25, the value is 18.97. This value is within the healthy range. It has increased from 13.66 (Mar 24) to 18.97, marking an increase of 5.31.
- For PBT Margin (%), as of Mar 25, the value is 17.68. This value is within the healthy range. It has increased from 12.10 (Mar 24) to 17.68, marking an increase of 5.58.
- For Net Profit Margin (%), as of Mar 25, the value is 14.55. This value exceeds the healthy maximum of 10. It has increased from 9.67 (Mar 24) to 14.55, marking an increase of 4.88.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.45. This value is within the healthy range. It has increased from 9.56 (Mar 24) to 14.45, marking an increase of 4.89.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.07. This value is within the healthy range. It has increased from 13.39 (Mar 24) to 19.07, marking an increase of 5.68.
- For Return on Capital Employeed (%), as of Mar 25, the value is 21.29. This value is within the healthy range. It has increased from 17.64 (Mar 24) to 21.29, marking an increase of 3.65.
- For Return On Assets (%), as of Mar 25, the value is 11.23. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 11.23, marking an increase of 3.26.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.10, marking an increase of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.29, marking an increase of 0.11.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. There is no change compared to the previous period (Mar 24) which recorded 0.85.
- For Current Ratio (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 1.87, marking an increase of 0.29.
- For Quick Ratio (X), as of Mar 25, the value is 1.26. This value is within the healthy range. It has increased from 0.99 (Mar 24) to 1.26, marking an increase of 0.27.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.35. This value is within the healthy range. It has increased from 0.87 (Mar 24) to 4.35, marking an increase of 3.48.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.11. This value is below the healthy minimum of 20. It has increased from 9.50 (Mar 24) to 11.11, marking an increase of 1.61.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.19. This value is below the healthy minimum of 20. It has increased from 5.85 (Mar 24) to 8.19, marking an increase of 2.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 88.89. This value exceeds the healthy maximum of 70. It has decreased from 90.50 (Mar 24) to 88.89, marking a decrease of 1.61.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.81. This value exceeds the healthy maximum of 70. It has decreased from 94.15 (Mar 24) to 91.81, marking a decrease of 2.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 18.58. This value is within the healthy range. It has increased from 12.61 (Mar 24) to 18.58, marking an increase of 5.97.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.21. This value is within the healthy range. It has increased from 7.21 (Mar 24) to 12.21, marking an increase of 5.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 94,555.16. It has increased from 75,275.95 (Mar 24) to 94,555.16, marking an increase of 19,279.21.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.16. This value exceeds the healthy maximum of 3. It has increased from 3.76 (Mar 24) to 4.16, marking an increase of 0.40.
- For EV / EBITDA (X), as of Mar 25, the value is 17.26. This value exceeds the healthy maximum of 15. It has decreased from 19.15 (Mar 24) to 17.26, marking a decrease of 1.89.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has increased from 3.68 (Mar 24) to 4.07, marking an increase of 0.39.
- For Retention Ratios (%), as of Mar 25, the value is 88.88. This value exceeds the healthy maximum of 70. It has decreased from 90.49 (Mar 24) to 88.88, marking a decrease of 1.61.
- For Price / BV (X), as of Mar 25, the value is 5.38. This value exceeds the healthy maximum of 3. It has increased from 5.16 (Mar 24) to 5.38, marking an increase of 0.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has increased from 3.68 (Mar 24) to 4.07, marking an increase of 0.39.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lupin Ltd:
- Net Profit Margin: 14.55%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 21.29% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.07% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.21
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.26
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 22.5 (Industry average Stock P/E: 46.55)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.29
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 14.55%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Kalpataru Inspire, 3rd Floor, Mumbai Maharashtra 400055 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. Manju D Gupta | Chairperson |
| Mr. Nilesh D Gupta | Managing Director |
| Ms. Vinita Gupta | Director & CEO |
| Mr. Ramesh Swaminathan | Executive Director & Global CFO |
| Mr. Mark D McDade | Independent Director |
| Dr. Punita Kumar-Sinha | Independent Director |
| Mr. Jean-Luc Belingard | Independent Director |
| Mr. Jeffrey Kindler | Independent Director |
| Mr. Alfonso Zulueta | Independent Director |
| Mr. K B S Anand | Independent Director |
| Mr. Punita Lal | Independent Director |
FAQ
What is the intrinsic value of Lupin Ltd?
Lupin Ltd's intrinsic value (as of 02 February 2026) is ₹4240.08 which is 99.16% higher the current market price of ₹2,129.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹97,150 Cr. market cap, FY2025-2026 high/low of ₹2,228/1,774, reserves of ₹19,541 Cr, and liabilities of ₹33,500 Cr.
What is the Market Cap of Lupin Ltd?
The Market Cap of Lupin Ltd is 97,150 Cr..
What is the current Stock Price of Lupin Ltd as on 02 February 2026?
The current stock price of Lupin Ltd as on 02 February 2026 is ₹2,129.
What is the High / Low of Lupin Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lupin Ltd stocks is ₹2,228/1,774.
What is the Stock P/E of Lupin Ltd?
The Stock P/E of Lupin Ltd is 22.5.
What is the Book Value of Lupin Ltd?
The Book Value of Lupin Ltd is 430.
What is the Dividend Yield of Lupin Ltd?
The Dividend Yield of Lupin Ltd is 0.56 %.
What is the ROCE of Lupin Ltd?
The ROCE of Lupin Ltd is 21.3 %.
What is the ROE of Lupin Ltd?
The ROE of Lupin Ltd is 20.6 %.
What is the Face Value of Lupin Ltd?
The Face Value of Lupin Ltd is 2.00.